低剂量白细胞介素-2使一名难治性系统性红斑狼疮患者迅速达到临床缓解 - Suppr

Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE.

作者信息

Humrich Jens Y, von Spee-Mayer Caroline, Siegert Elise, Alexander Tobias, Hiepe Falk, Radbruch Andreas, Burmester Gerd-Rüdiger, Riemekasten Gabriela

机构信息

Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany.

German Rheumatism Research Center (DRFZ), a Leibniz Institute, Berlin, Germany.

出版信息

Ann Rheum Dis. 2015 Apr;74(4):791-2. doi: 10.1136/annrheumdis-2014-206506. Epub 2015 Jan 21.

DOI:10.1136/annrheumdis-2014-206506

PMID:25609413

Abstract

摘要

相似文献

Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE.

Ann Rheum Dis. 2015 Apr;74(4):791-2. doi: 10.1136/annrheumdis-2014-206506. Epub 2015 Jan 21.

Clinical, biological and ultrasonographic remission in a patient with musculoskeletal systemic lupus erythematosus with rituximab.

Lupus. 2009 Mar;18(3):270-2. doi: 10.1177/0961203308095001.

Successful treatment of systemic lupus erythematosus with subcutaneous immunoglobulin.

Lupus. 2016 May;25(6):663-5. doi: 10.1177/0961203316630116. Epub 2016 Feb 3.

Successful outcomes with rituximab therapy for refractory childhood systemic lupus erythematosus.

Pediatr Nephrol. 2006 Apr;21(4):598-9. doi: 10.1007/s00467-006-0024-7. Epub 2006 Mar 1.

Successful rituximab treatment of refractory hemophagocytic lymphohistiocytosis and autoimmune hemolytic anemia associated with systemic lupus erythematosus.

Mod Rheumatol. 2014 Sep;24(5):855-7. doi: 10.3109/14397595.2013.874740. Epub 2014 Feb 11.

Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a series of 52 patients from a single centre.

Clin Exp Rheumatol. 2014 Jan-Feb;32(1):41-7. Epub 2013 Sep 12.

Rituximab-induced long-term remission in two children with SLE.

Eur J Pediatr. 2007 Feb;166(2):177-81. doi: 10.1007/s00431-006-0217-x. Epub 2006 Aug 17.

Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.

Lupus. 2013 Jun;22(7):664-74. doi: 10.1177/0961203313485489. Epub 2013 Apr 23.

Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial.

Ann Rheum Dis. 2020 Jan;79(1):141-149. doi: 10.1136/annrheumdis-2019-215396. Epub 2019 Sep 19.

Increase of peripheral T regulatory cells during remission induction with cyclophosphamide in active systemic lupus erythematosus.

Int J Rheum Dis. 2014 Sep;17(7):790-5. doi: 10.1111/1756-185X.12500.

引用本文的文献

Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: single ascending dose and multiple ascending dose trial data.

Immunohorizons. 2025 Mar 26;9(5). doi: 10.1093/immhor/vlaf005.

Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics.

Signal Transduct Target Ther. 2025 Mar 17;10(1):102. doi: 10.1038/s41392-025-02168-0.

Promises and Pitfalls of Next-Generation Treg Adoptive Immunotherapy.

Cancers (Basel). 2023 Dec 17;15(24):5877. doi: 10.3390/cancers15245877.

Low-dose interleukin-2 therapy in systemic lupus erythematosus.

Rheumatol Immunol Res. 2023 Sep 27;4(3):150-156. doi: 10.2478/rir-2023-0021. eCollection 2023 Sep.

Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus.

Front Immunol. 2023 Sep 12;14:1230264. doi: 10.3389/fimmu.2023.1230264. eCollection 2023.

Increased serum soluble interleukin-2 receptor levels in dermatomyositis are associated with Th17/Treg immune imbalance.

Clin Exp Med. 2023 Nov;23(7):3605-3617. doi: 10.1007/s10238-023-01155-5. Epub 2023 Aug 2.

A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases.

EBioMedicine. 2023 Apr;90:104539. doi: 10.1016/j.ebiom.2023.104539. Epub 2023 Mar 31.

The emerging role of regulatory cell-based therapy in autoimmune disease.

Front Immunol. 2022 Dec 14;13:1075813. doi: 10.3389/fimmu.2022.1075813. eCollection 2022.

Unraveling the Link between Interferon-α and Systemic Lupus Erythematosus: From the Molecular Mechanisms to Target Therapies.

Int J Mol Sci. 2022 Dec 15;23(24):15998. doi: 10.3390/ijms232415998.

Low-Dose rIL-15 Protects from Nephrotoxic Serum Nephritis via CD8 T Cells.

Cells. 2022 Nov 18;11(22):3656. doi: 10.3390/cells11223656.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE.

作者信息

Humrich Jens Y, von Spee-Mayer Caroline, Siegert Elise, Alexander Tobias, Hiepe Falk, Radbruch Andreas, Burmester Gerd-Rüdiger, Riemekasten Gabriela

机构信息

Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany.

German Rheumatism Research Center (DRFZ), a Leibniz Institute, Berlin, Germany.

出版信息

Ann Rheum Dis. 2015 Apr;74(4):791-2. doi: 10.1136/annrheumdis-2014-206506. Epub 2015 Jan 21.

DOI:10.1136/annrheumdis-2014-206506

PMID:25609413

Abstract

摘要

相似文献

Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE.

Ann Rheum Dis. 2015 Apr;74(4):791-2. doi: 10.1136/annrheumdis-2014-206506. Epub 2015 Jan 21.

Clinical, biological and ultrasonographic remission in a patient with musculoskeletal systemic lupus erythematosus with rituximab.

Lupus. 2009 Mar;18(3):270-2. doi: 10.1177/0961203308095001.

Successful treatment of systemic lupus erythematosus with subcutaneous immunoglobulin.

Lupus. 2016 May;25(6):663-5. doi: 10.1177/0961203316630116. Epub 2016 Feb 3.

Successful outcomes with rituximab therapy for refractory childhood systemic lupus erythematosus.

Pediatr Nephrol. 2006 Apr;21(4):598-9. doi: 10.1007/s00467-006-0024-7. Epub 2006 Mar 1.

Successful rituximab treatment of refractory hemophagocytic lymphohistiocytosis and autoimmune hemolytic anemia associated with systemic lupus erythematosus.

Mod Rheumatol. 2014 Sep;24(5):855-7. doi: 10.3109/14397595.2013.874740. Epub 2014 Feb 11.

Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a series of 52 patients from a single centre.

Clin Exp Rheumatol. 2014 Jan-Feb;32(1):41-7. Epub 2013 Sep 12.

Rituximab-induced long-term remission in two children with SLE.

Eur J Pediatr. 2007 Feb;166(2):177-81. doi: 10.1007/s00431-006-0217-x. Epub 2006 Aug 17.

Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.

Lupus. 2013 Jun;22(7):664-74. doi: 10.1177/0961203313485489. Epub 2013 Apr 23.

Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial.

Ann Rheum Dis. 2020 Jan;79(1):141-149. doi: 10.1136/annrheumdis-2019-215396. Epub 2019 Sep 19.

Increase of peripheral T regulatory cells during remission induction with cyclophosphamide in active systemic lupus erythematosus.

Int J Rheum Dis. 2014 Sep;17(7):790-5. doi: 10.1111/1756-185X.12500.

引用本文的文献

Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: single ascending dose and multiple ascending dose trial data.

Immunohorizons. 2025 Mar 26;9(5). doi: 10.1093/immhor/vlaf005.

Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics.

Signal Transduct Target Ther. 2025 Mar 17;10(1):102. doi: 10.1038/s41392-025-02168-0.

Promises and Pitfalls of Next-Generation Treg Adoptive Immunotherapy.

Cancers (Basel). 2023 Dec 17;15(24):5877. doi: 10.3390/cancers15245877.

Low-dose interleukin-2 therapy in systemic lupus erythematosus.

Rheumatol Immunol Res. 2023 Sep 27;4(3):150-156. doi: 10.2478/rir-2023-0021. eCollection 2023 Sep.

Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus.

Front Immunol. 2023 Sep 12;14:1230264. doi: 10.3389/fimmu.2023.1230264. eCollection 2023.

Increased serum soluble interleukin-2 receptor levels in dermatomyositis are associated with Th17/Treg immune imbalance.

Clin Exp Med. 2023 Nov;23(7):3605-3617. doi: 10.1007/s10238-023-01155-5. Epub 2023 Aug 2.

A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases.

EBioMedicine. 2023 Apr;90:104539. doi: 10.1016/j.ebiom.2023.104539. Epub 2023 Mar 31.

The emerging role of regulatory cell-based therapy in autoimmune disease.

Front Immunol. 2022 Dec 14;13:1075813. doi: 10.3389/fimmu.2022.1075813. eCollection 2022.

Unraveling the Link between Interferon-α and Systemic Lupus Erythematosus: From the Molecular Mechanisms to Target Therapies.

Int J Mol Sci. 2022 Dec 15;23(24):15998. doi: 10.3390/ijms232415998.

Low-Dose rIL-15 Protects from Nephrotoxic Serum Nephritis via CD8 T Cells.

Cells. 2022 Nov 18;11(22):3656. doi: 10.3390/cells11223656.

Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE.

作者信息

机构信息

出版信息

相似文献

引用本文的文献